<DOC>
	<DOCNO>NCT00374699</DOCNO>
	<brief_summary>Peripheral T-cell lymphoma ( PTCLs ) neoplasias post-thymic T-cells different stage differentiation heterogeneous group malignancy present different morphological pattern , phenotype , clinical presentation . These tumour strike epidemiological distribution lower incidence Western country Asia . In Korea , PTCLs include T- natural killer ( NK ) -cell lymphomas constitute approximately 25 35 % non-Hodgkin 's lymphoma . This incidence quite similar Eastern Asian country , include Japan , Hong Kong , China . Recent study suggest T-cell phenotype independent significant prognostic factor , PTCLs one low overall survival failure-free survival rate . Based investigator 's experience , overall complete remission rate 61.2 % ( 95 % confidence interval [ CI ] : 48.5-72.8 % ) 5-year probability failure-free survival 33.5 % . Median survival patient 45 month ( range 0-64+ month ) 5-year probability survival 36.2 % . Rassidakis et al . report expression pro-apoptotic protein BAX BCL-XS , may explain poor response many type PTCL standard chemotherapy . To overcome poor outcome , optimal therapy PTCLs remain define . However , rarity disease Western country , trial report . Bortezomib ( Velcade ) modify dipeptidyl boronic acid , reversible inhibitor chymotrypsin-like activity 26S proteosome . Bortezomib may induce tumor cell apoptosis decrease bcl-2 associate drug resistance . Through phase II study , single agent bortezomib patient relapse indolent mantle cell lymphoma show activity . And also preliminary data indicate bortezomib safely administer combination dose adjust etoposide , prednisolone , vincristine , cyclophosphamide doxorubicin ( EPOCH ) chemotherapy . Therefore , possible improve poor outcome patient PTCLs combination cyclophosphamide , doxorubicin , vincristine , prednisolone ( CHOP ) bortezomib first-line therapy . Primary Hypothesis : Based clinical trial experimental data , bortezomib overcome pro-apoptotic protein BAX BCL-XS induced drug resistance .</brief_summary>
	<brief_title>Bortezomib CHOP Patients With Advanced Stage Aggressive T Cell Natural Killer ( NK ) /T Cell Lymphomas</brief_title>
	<detailed_description />
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Lymphoma , Non-Hodgkin</mesh_term>
	<mesh_term>Lymphoma , T-Cell</mesh_term>
	<mesh_term>Lymphoma , T-Cell , Peripheral</mesh_term>
	<mesh_term>Bortezomib</mesh_term>
	<criteria>Histologically confirm PTCLs NK/T cell lymphoma exclude anaplastic lymphoma kinase ( ALK ) positive anaplastic large cell Tcell lymphoma ( ALCL ) Performance status ( ECOG ) ≤ 3 Age ≤ 65 At least one unidimensionally measurable lesion ( ) ≥ 2 cm conventional compute tomography ( CT ) ≥ 1 cm spiral CT skin lesion ( photograph take ) measurable lesion physical examination Laboratory value Creatinine ( Cr ) &lt; 1.5 mg % creatinine clearance ( Ccr ) &gt; 50 ml/min Transaminase &lt; 3 X upper normal value Bilirubin &lt; 2.0 mg/dl Absolute neutrophil count ( ANC ) &gt; 1,500/ul Platelets &gt; 75,000/ul Informed consent Ann Arbor stage III IV Any malignancy within past 5 year except basal cell skin cancer carcinoma situ ( CIS ) cervix Serious comorbid diseases Pregnancy breast feed Any waiver inclusion exclusion criterion must approve investigator sponsor casebycase basis prior enrol subject . This must document sponsor investigator . No subject allow enroll study .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>June 2007</verification_date>
	<keyword>Velcade</keyword>
	<keyword>Bortezomib</keyword>
	<keyword>CHOP</keyword>
	<keyword>Peripheral T-cell lymphoma ( PTCLs )</keyword>
	<keyword>natural killer ( NK ) -cell lymphoma</keyword>
</DOC>